Palliative Treatments for Patients With Advanced Hepatocellular Carcinoma (HCC)
Status:
Completed
Trial end date:
2018-01-01
Target enrollment:
Participant gender:
Summary
The standard treatment choice for advanced hepatocellular carcinoma (HCC) is sorafenib, and
its efficacy is limited. More active treatments were performed in patients with advanced HCC
in China, which include radical hepatectomy or TACE. The study is to investigate whether the
active treatment will profit survival of patients, and to evaluate the safety.